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(±20.9) letters in group II (p = 0.326). This result was achieved 
with significantly fewer injections in group II. Additionally, 
30% of the eyes in group II did not need ranibizumab IVI dur-
ing the 12 months of the trial.  Conclusion: Ranibizumab IVI 
in addition to IH proved to be highly effective in increasing 
visual acuity and reducing macular edema secondary to 
CRVO. Initial IH in early CRVO may be a first treatment option 
in patients anxious about IVI.  © 2014 S. Karger AG, Basel 
 Introduction 
 Central retinal vein occlusion (CRVO) is the second 
most frequent retinal vascular disease with a prevalence 
between 0.3 and 0.6%  [1] . For decades, treatment was 
largely based on the results of the Central Vein Occlusion 
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 Abstract 
 Purpose: This is a prospective, randomized, multicenter, in-
vestigator-initiated trial to evaluate the 12-month effective-
ness of isovolemic hemodilution (IH) with prompt versus de-
ferred intravitreal injections (IVI) of ranibizumab 0.5 mg for 
the treatment of macular edema secondary to early central 
retinal vein occlusion (CRVO).  Methods: Eyes with macular 
edema due to CRVO having occurred not more than 8 weeks 
previously received either monthly ranibizumab IVI in com-
bination with IH (group I, n = 28) or IH alone (group II, n = 30). 
From month 2 to 12, the patients in both groups could be 
treated with monthly intravitreal ranibizumab. The main 
outcome variables were gain of visual acuity and the course 
of central retinal thickness as measured with optical coher-
ence tomography.  Results: At 12 months, eyes in group I 
on average gained +28.1 (±19.3) letters compared to +25.2 
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Study  [2] . As a result, only panretinal laser photocoagula-
tion in pronounced ischemic cases proved to prevent fur-
ther complications, but it did not improve visual recovery 
 [3] . In the early 1980s, Hansen et al.  [4] showed favorable 
results concerning visual acuity in CRVO when treated 
with isovolemic hemodilution (IH) which was initiated 
early (duration of symptoms <8 weeks). Similar results 
have also been described by Glacet-Bernard et al.  [5, 6] . 
Though based on a well-performed clinical trial, due to 
the small study sample, their IH results did not find 
worldwide acceptance as a general treatment regimen in 
CRVO  [7] . In Germany, IH is commonly considered a 
primary treatment option  [8] .
 In recent years, intravitreal pharmaceutical blockage 
of vascular endothelial growth factor (VEGF) has shown 
efficacy in the treatment of CRVO  [9–11] . Early noncom-
parative clinical trials using intravitreal bevacizumab 
(Avastin TM ; Roche Pharma AG, Grenzach-Wyhlen, Ger-
many), a monoclonal antibody binding and deactivating 
VEGF molecules, found favorable results of visual acuity 
recovery in CRVO. Primarily developed as an intrave-
nous treatment of gastrointestinal cancer, the therapy re-
mained off label. Ranibizumab (Lucentis TM ; Novartis 
Pharma GmbH, Basel, Switzerland), a smaller antibody 
with the same binding region developed and approved for 
the intravitreal treatment of age-related macular degen-
eration, was efficacious in a prospective, randomized, 
clinical trial in CRVO patients up to 24 months. Approv-
al for macular edema in central and branch retinal vein 
occlusion followed in 2011. In the CRUISE study, patients 
treated with monthly ranibizumab 0.5 mg improved by 
14.9 letters at month 6 in contrast to 0.8 letters in the con-
trol group  [12] . In 2007, the RAVO study, a multicenter, 
prospective, randomized trial in Germany, was initiated 
to evaluate the effectiveness of intravitreal treatment with 
ranibizumab 0.5 mg in combination with IH compared to 
IH alone followed by ranibizumab 0.5 mg in a pro re nata 
(PRN) regimen for patients with macular edema due to 
fresh CRVO (duration of symptoms <8 weeks). The main 
outcome parameters of this study were gain of visual acu-
ity, the course of central retinal thickness (CRT) and the 
number of injections.
 Methods 
 The RAVO trial is an open, prospective, randomized, con-
trolled, multicenter, investigator-initiated clinical trial to evaluate 
the 12-month effectiveness of IH with prompt versus deferred in-
travitreal injections (IVI) of ranibizumab 0.5 mg for the treatment 
of macular edema secondary to early CRVO. 
 The study was performed in accordance with the tenets of the 
Declaration of Helsinki. All patients gave their informed consent 
prior to any study-related procedures. The study was accepted by 
the ethics committees at each study site as well as by the federal 
authorities. This trial is registered under EudraCT No. 2006-
005450-71.
 The RAVO study aimed at enrolling 60 patients (30 per group) 
with macular edema secondary to CRVO. Only one eye per patient 
could be included. The main inclusion and exclusion criteria are 
summarized in  table 1 . Only treatment-naive patients with CRVO 
over a period of no more than 8 weeks were included.
 Primary and Secondary Endpoints 
 The primary endpoints were visual acuity results on the Early 
Treatment Diabetic Retinopathy Study (ETDRS) chart and macu-
lar edema after 8 weeks (2 months). The secondary endpoints were 
visual acuity results and macular edema after 52 weeks (12 months). 
Additional endpoints were percentages of patients gaining  ≥ 3 
lines on the ETDRS chart, the number of injections and treatment 
safety after 12 months.
 At every visit, visual acuity was tested according to the ETDRS 
guidelines, CRT was measured with a Stratus OCT-3000 device 
(Carl Zeiss Meditec, Dublin, Calif., USA) via a fast macular scan, 
fundus photographs were taken of the central temporal 30°, and a 
full ophthalmic evaluation with dilated fundus biomicroscopy was 
performed. At baseline as well as at months 2, 6 and 12, fluores-
cein angiography was performed. Blood pressure measurements 
and blood samples were taken at baseline and at every visit during 
the first 8 weeks. The blood examination consisted of a blood 
count, hematocrit and coagulation parameters (international nor-
malized ratio and partial thromboplastin time). At baseline, the 
erythrocyte sedimentation rate as well as C-reactive protein and 
serum creatinine levels were acquired.
 Treatment 
 Treatment in both groups consisted of IH starting within 3 days 
of enrollment. IH was performed by full venous blood extraction 
of 500 ml into a blood donation bag from one arm and simultane-
ous venous infusion of 500 ml 6% hydroxyethyl starch by way of 
the contralateral arm  [13] . This procedure was repeated within the 
first week until a hematocrit level of 36% was reached. If hemato-
crit levels during the first 8 weeks rose above 38%, IH was repeated. 
Visits were scheduled every 2 weeks during the first 8 weeks and 
then on a 4-weekly basis. In group I, the patients additionally re-
ceived monthly IVI of ranibizumab 0.5 mg, initiated within the 
first week of enrollment on a PRN basis. In both groups, the pa-
tients received IVI of ranibizumab 0.5 mg on a PRN basis from 
week 8 onwards if the following criteria for injection were met: 
visual acuity <20/25 and/or CRT >225 μm on optical coherence 
tomography (OCT). In both groups, IVI were discontinued if the 
following criteria were met: visual acuity >20/25 and/or CRT <225 
μm on OCT.
 IVI Technique 
 Before each scheduled IVI, the patients received polymyxin B, 
neomycin and bacitracin eyedrops 4 times for 3 days (Polyspec-
tran; Alcon Pharma GmbH, Freiburg, Germany). Topical anesthe-
sia before IVI was performed at least 3 times using tetracaine 1% 
eyedrops. Before injection, the brow, upper and lower eyelids and 




















   
   
   
   
   
   
   
   
   
   
   


























orbital areas were scrubbed with povidone-iodine 10%, and the 
conjunctiva was irrigated with 10 ml of povidone-iodine 1% (Be-
tadine; Alcon, Fort Worth, Tex., USA) through the upper and low-
er fornices. After application of a sterile drape, a lid speculum was 
inserted. The patients received 1 unilateral IVI (ranibizumab 0.5 
mg/0.05 ml) using a sharp 27-gauge needle at a distance of 3.5 and 
4.0 mm from the limbus in pseudophakic and phakic eyes, respec-
tively. The needle was carefully removed using a sterile cotton ap-
plicator to prevent reflux. After the injection, the patients were 
asked to continue to self-administer antibiotic eyedrops (polymyx-
in B, neomycin and bacitracin) for 3 more days 4 times per day. 
The drug (0.1 ml) was drawn under sterile conditions from a ra-
nibizumab 1.0 mg/ml container.
 Randomization 
 Randomization was performed by means of an Excel (Micro-
soft, Seattle, Wash., USA) calculation randomly producing the 
numbers ‘1’ (for group I) and ‘2’ (for group II), specifying 30 values 
per group. Consecutive patients at all sites were assigned to their 
treatment group according to the resulting randomization list. 
 Statistical Analysis and Sample Size Calculation 
 Statistical analysis was performed with the SPSS software ver-
sion 19.0 (SPSS Inc., Chicago, Ill., USA). For comparison of pa-
rameters between groups, the Mann-Whitney U test was used. For 
comparison of data within groups at different time points, the Wil-
coxon test was performed. p < 0.05 was considered statistically 
significant. 
 The sample size calculation resulted in 23 patients per group. 
This was based on the following assumptions: a visual improve-
ment of 3 lines was considered a clinically relevant benefit (suc-
cess) irrespective of baseline visual acuity. Preliminary studies by 
the authors had resulted in a proportion of 20% of patients treat-
ed with IH alone improving by  ≥ 3 lines  [4, 14] . Of patients treat-
ed with VEGF inhibitors alone, a proportion of >55% improved 
by  ≥ 3 lines  [9] . Consequently, the present randomized trial 
should be large enough to reject the null hypothesis of equal suc-
cess rates in the IH and IH-plus-anti-VEGF groups (significance 
level, α = 5%) with a probability (power) of 80% if the true success 
rates are 20% for IH and 55% for IH plus anti-VEGF. Based on 
the arcsin approximation, at least 23 patients per group were 
needed to achieve this goal. It was planned that approximately 60 
patients would be screened to achieve a sample size of approxi-
mately 55 eligible patients within an estimated 12-month recruit-
ment period. It was also expected that, of these patients, approx-
imately 50 would complete the treatment through week 52, i.e. the 
time point for the secondary endpoint without major protocol 
violations.
 Table 1. Inclusion and exclusion criteria of the RAVO study
Inclusion criteria
Best-corrected visual acuity at baseline in the study eye between 5 and 65 letters using an ETDRS
chart measured at 4 m or at 1 m
Cystoid macular edema secondary to CRVO of ≥250 μm
Maximum duration of symptoms: 8 weeks
Willingness and ability to follow the study protocol
Exclusion criteria
History of systemic corticosteroids within 2 months prior to randomization or topical, rectal or inhaled
corticosteroids in current use >2 times per week
Significant ischemic heart disease or heart insufficiency (NYHA grade III–IV)
State after cerebrovascular ischemic event 
Grossly abnormal creatinine and electrolyte levels and/or chronic renal failure
Significant pulmonary disease
Uncontrolled arterial hypertension: systolic blood pressure ≥150 and/or diastolic blood pressure ≥95 mm Hg
Active systemic infection
Known malignancies (treated/untreated)
Use of specific anticoagulants during the study: Coumadin, warfarin, combination of aspirin and
clopidogrel
Pregnancy or nursing
Hematocrit (packed cell volume) below 0.37
Ocular diseases preventing visual recovery
Macular/retinal disease, e.g. vitreomacular traction, epiretinal membrane, age-related macular 
degeneration, diabetic retinopathy, state after retinal detachment
Preexisting intraocular and ocular inflammation
Any concurrent disease in the study eye that could compromise visual acuity or require medical or surgical 
intervention during the study period
Uncontrolled glaucoma or low-tension glaucoma in the study eye
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 Study recruitment was terminated when 58 patients 
were included: 28 patients in group I and 30 patients in 
group II. Up to that point, no dropout or loss to follow-up 
had occurred within the study period. All patients but 1 
in group II completed the full 12-month study. This pa-
tient dropped out after 6 months of follow-up because he 
moved abroad for work reasons. Data on this patient were 
included in the intention-to-treat analysis using the last-
observation-carried-forward method.  Table 2 shows the 
patient characteristics for both groups. No significant dif-
ferences were found for visual acuity at baseline and for 
age ( table 2 ). A significant difference was found for later-
ality of the affected eye and gender distribution between 
the groups. Another significant difference was found for 
mean duration of symptoms, which was 2.9 weeks (min. 
1.0, max. 7.0) in group I and 2.0 weeks (min. 1.0, max. 7.0) 
in group II (p = 0.022). Though eyes in group I on average 
had slightly worse baseline ETDRS letter scores at 32.4 
(±21.1) letters compared to eyes in group II with 38.3 
(±24.6) letters at baseline, no statistical significance was 
found (p = 0.304) ( table 2 ;  fig. 1 a).
 Visual Acuity 
 At the end of month 2 (i.e. the primary endpoint, at 
which, in group II, IVI of ranibizumab 0.5 mg could be 
initiated) ETDRS letter scores in group I eyes had sig-
nificantly improved to 53.3 (±18.9) letters (p < 0.001) 
compared to only a slight improvement in group II eyes 
with 43.7 (±28.5) letters (p = 0.030). Nonetheless, sta-
tistical analysis detected no significant difference in vi-
sual acuity between the groups at month 2 (p = 0.279). 
Looking at the mean change in letters (ETDRS) after 
2 months of treatment, the eyes showed an increase 
of +20.9 (±21.4) letters in group I compared to +5.4 
(±19.4) letters in group II (p = 0.006) ( fig. 1 b). At month 
6, the mean visual acuity was 56.8 (±23.0) letters in 
group I compared to 63.0 (±19.7) in group II, and the 
mean changes in letters were +24.4 (±20.1, group I) and 
+24.7 (±18.4, group II; p = 0.957). At the secondary 
endpoint at 12 months, group I showed a mean ETDRS 
letter score of 60.5 (±22.9) letters compared to 62.6 
(±22.3) letters in group II (p = 0.649), and the mean 
change in visual acuity was +28.1 (±19.3) letters in 
group I compared to +25.2 (±20.9) letters in group II 
(p = 0.326). An improvement of  ≥ 3 lines ( ≥ 15 letters) 
 Table 2. Patient characteristics in the RAVO study
Group I Group II p*
Patients, n 28 30
Age (min./max.), years 61.0 (21/88) 60.9 (34/87) 0.467
Gender (male/female), n 21/7 14/16 0.028
Eye (OD/OS), n 9/19 22/8 0.002
Duration of symptoms, weeks 2.93 2.0 0.022
Visual acuity, ETDRS letters
Baseline 32.4 38.3 0.304
2 months 53.3 43.7 0.327
6 months 56.8 63.0 0.311
12 months 60.5 62.6 0.649
CRT, μm
Baseline 725 616 0.125
2 months 424 576 0.024
6 months 367 290 0.148
12 months 278 251 0.666
Hematocrit, vol%
Baseline 40.3 42.6 0.123
2 months 38.2 38.8 0.510
6 months 38.8 39.2 0.457
12 months 38.9 39.3 0.291
Injections (min./max.) at 12 months, n 5.5 (1/11) 3.2 (0/9) 0.004
Hemodilutions during first 2 months, n 1.5 1.8 0.08
Values apart from number of patients, gender and eye are expressed as means. OD = Right eye; OS = left eye; 




















   
   
   
   
   
   
   
   
   
   
   


























at 12 months was found in 21 of the 28 eyes (75%) in 
group I and in 20 of the 30 eyes (67%) in group II (p = 
0.570, χ 2 test).
 Central Retinal Thickness 
 The mean CRT at baseline was 725 (±258) μm in group 
I compared to 616 (±227) μm in group II (p = 0.125) 
( fig. 2 a). After 2 months of treatment with IH and IVI, the 
mean CRT decreased to 424 (±268) μm in group I, while 
IH alone caused only a small decrease to 576 (±312) μm 
in group II (p = 0.024). The change in CRT was –301 
(±298) μm in group I compared to –40 (±335) μm in 
group II (p = 0.002) ( fig. 2 b). At 6 months, after possible 
PRN initiation of ranibizumab treatment in group II eyes, 
the mean CRT measured in group I was 367 (±199) μm 
compared to 290 (±111) μm in group II (p = 0.148). There 
were comparable decreases in mean CRT of –358 (±290) 
μm and –326 (±244) μm at 6 months in group I and group 
II, respectively (p = 0.779). At month 12 (the secondary 
endpoint), in group I eyes, the mean CRT had decreased 
to 278 (±139) μm compared to 251 (±87) μm in group II 
eyes (p = 0.666). The mean reductions of CRT compared 
to baseline were –447 (±268) μm in group I and –359 
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 Fig. 1.  a Mean ETDRS letter score (±SE) in 
group I (IH with prompt IVI of ranibizu-
mab 0.5 mg) and group II (IH with IVI of 
ranibizumab 0.5 mg deferred for 2 months). 
 b Mean change in best-corrected visual 
acuity in ETDRS letters (±SE) compared to 
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 Rheologic Outcome and Number of IVI 
 During the first 2, months both groups received manda-
tory IH in order to decrease the hematocrit levels for better 
perfusion. No complications were noted due to IH. The 
baseline hematocrit levels were 40.3 vol% (group I) and 42.6 
vol% (group II; p = 0.123). At month 2, the average hema-
tocrit levels in group I had decreased to 38.2 vol% compared 
to 38.8 vol% in group II (p = 0.510). In both groups, the 
reduction in hematocrit levels was statistically significant 
(p = 0.010 and p < 0.001, respectively; Wilcoxon test). 
 The mean number of IVI after 12 months was signifi-
cantly higher in group I with 5.5 IVI (min. 1, max. 11) 
than in group II with 3.2 IVI (min. 0, max. 9; p = 0.003). 
Considering the earlier initiation of IVI of ranibizumab 
0.5 mg in group I, we compared the amount of injections 
up to month 10 in group I with the number of IVI per-
formed from month 2 up to month 12 in group II. The 
result was consistent with the primary calculation with 
5.2 IVI (min. 1, max. 9) in group I compared to 3.2 IVI 
(min. 0, max. 9) in group II (p = 0.006). In group II, in 
which intravitreal treatment with ranibizumab could be 
initiated after 2 months, 10 of the 30 patients (30%) did 
not receive any ranibizumab treatment during the whole 
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 Fig. 2.  a Mean CRT (±SE) in group I (IH 
with prompt IVI of ranibizumab 0.5 mg) 
and group II (IH with IVI of ranibizumab 
0.5 mg deferred for 2 months).  b Mean 
change in CRT (±SE) compared to baseline 




















   
   
   
   
   
   
   
   
   
   
   


























 Adverse Events 
 Adverse events are summarized in  table 3 . No serious 
ocular and systemic adverse events occurred during the 
study period. One eye in each group developed rubeosis 
iridis and was treated with panretinal photocoagula-
tion. The neovascularization of the iris dissolved in 
both cases. 
 Discussion 
 The role of VEGF in the pathogenesis of macular 
edema secondary to CRVO has been postulated on the 
basis of raised protein levels in vitreous gel samples of 
eyes with CRVO  [15] . Early treatment strategies used 
bevacizumab to reduce the amount of VEGF in venous 
occlusive disease  [9, 11, 16] . Ranibizumab, a monoclo-
nal antibody against VEGF with good retinal penetra-
tion, had been primarily developed for the treatment of 
neovascular age-related macular degeneration  [17, 18] 
and later proved effective for the treatment of macular 
edema following CRVO  [12, 19] . Ranibizumab aims at 
reducing the effects of complications succeeding the ve-
nous occlusion. Whether it increases the likelihood of 
reperfusion remains unclear. According to the German 
guidelines for the therapy of macular edema after retinal 
vein occlusion, patients were treated with IH to enhance 
venous perfusion by increasing blood viscosity. Though 
it would have been more appropriate to compare the 
treatment group with ranibizumab to a group without 
any anti-VEGF treatment, based on the initial experi-
ences with bevacizumab at the start of the trial, the au-
thors considered such a protocol unethical, and it would 
also have been impossible to recruit a full study popula-
tion as, predictably, there would have been high drop-
out rates from a group without intravitreal treatment. 
Therefore, a possibility for delayed anti-VEGF treat-
ment was built into the protocol at month 2 for group 
II patients. 
 In the RAVO trial, we found a significant difference 
between IH in combination with prompt IVI of ranibi-
zumab 0.5 mg (group I) and IH with IVI deferred until 
month 2 (group II). The mean letter gains after 4 and 8 
weeks were significantly higher in group I than group II 
eyes (p < 0.001 each). In accordance with this, a signifi-
cantly higher reduction of CRT was found by OCT in 
group I at months 1 and 2 compared to group II (p < 0.001 
each). IH plus IVI of ranibizumab resulted in a fast in-
crease in visual acuity via a rapid reduction of macular 
edema (group I). In group II, where only IH was per-
formed during the first 2 months, on average a lesser but 
still significant increase in visual acuity was found at both 
months (month 1, p = 0.049; month 2, p = 0.030) but with 
no significant decrease in macular edema (p = 0.147 and 
p = 0.673, respectively). 
 Interestingly, the benefit achieved in group I eyes 
compared to that in group II during the first 2 months 
tapered off when, in group II, for eyes with persistent 
macular edema at month 2, IVI treatment with ranibi-
zumab was initiated if needed. At months 3–12, no sig-
nificant difference concerning visual acuity and macu-
lar edema could be found between the two groups. The 
same applied to the amount of letters gained on the 
 ETDRS chart as well as the reduction of macular edema. 
Only at month 4 did group I eyes show a significantly 
higher gain in letters compared to group II eyes (p = 
0.049). From month 5 onwards, eyes in group II even 
showed slightly better ETDRS letter scores than eyes in 
group I. This may be due to recurrences of macular ede-
ma in some eyes in group I. In group II, on the other 
hand, at 5 months most eyes that needed it were given 
an intravitreal ranibizumab upload treatment, which re-
sulted in a lower percentage of eyes with variability in 
visual acuity.
 Compared to IH alone, combined treatment with ra-
nibizumab showed an enhanced effect on visual acuity 
recovery and the reduction of macular edema in the ini-
tial phase of the study (first 2 months). Though we did not 
compare ranibizumab treatment alone to only hemodilu-
tion, one can assume that the effect in group I may be due 
to ranibizumab. In group II, we could also find a signifi-
cant effect on visual acuity but no significant reduction of 
macular edema. On the other hand, a noteworthy one 
third of eyes in group II recovered from their CRVO with 
IH treatment alone and without further need for IVI dur-
ing the whole study period. In fact, the delayed introduc-





Iris neovascularization 1 (4%) 1 (4%)
Retinal detachment 0 0
Endophthalmitis 0 0
Episode of depression 1 (4%) 0
Ischemic stroke 0 0
Angina pectoris 0 0
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tion of ranibizumab treatment – at least in our cohort of 
rather new and previously untreated cases – did not result 
in a less favorable outcome after 12 months, at least with 
a 2-month delayed initiation of IVI treatment. In con-
trast, the ROCC trial showed a marked decline in visual 
acuity in the no-treatment group during the first 2 months 
 [20] . In our cohort, group II eyes with IH gained some 
letters within this period. 
 Additionally, in our study, the delayed anti-VEGF 
treatment but early IH resulted in a significantly lower 
need for ranibizumab injections at 12 months and, con-
sequentially, reduced treatment costs. Our results for the 
effectiveness of hemodilution in CRVO therapy confirm 
data from two randomized, controlled trials by Glacet-
Bernard et al.  [5, 6] . 
 No significant differences in complications were found 
between the two groups. In 1 patient each, panretinal la-
ser photocoagulation was needed in order to treat neovas-
cularization of the iris. In this study, the treatment success 
was considerable compared to earlier and recent investi-
gations. Eyes in the RAVO study reached a mean final 
visual acuity of 60.5 ETDRS letters in group I and 62.6 
letters in group II. An increase of  ≥ 3 lines from baseline 
to 12 months was found in 75% (group I) and 67% (group 
II) of the eyes, respectively.
 Epstein et al.  [21, 22] , in a randomized, controlled tri-
al evaluating the effectiveness of intravitreal bevacizumab 
1.25 mg every 6 weeks for the treatment of CRVO, found 
gains of  ≥ 3 lines in 60% of the eyes at 6 and 12 months, 
respectively, in their treatment group.
 In the CRUISE trial, evaluating a 0.3- and a 0.5-mg 
 intravitreal regimen with ranibizumab versus sham treat-
ment, Brown et al.  [12] and Campochiaro et al.  [23] re-
ported a mean visual acuity increase of 12.7 and 14.9 let-
ters after 6 months, respectively, in the treatment groups, 
and of 13.9 letters in both groups at 12 months. The per-
centages of patients gaining  ≥ 3 lines on the ETDRS chart 
were 22 and 27%, respectively, at 6 months, and 47 and 
51%, respectively, at 12 months.
 In the ROCC trial, comparing an intravitreal treat-
ment regimen of 0.5 mg of ranibizumab to sham treat-
ment, eyes in the treatment group showed a mean visual 
acuity gain of 12 letters after 6 months  [20] . Reasons for 
the remarkable results in the RAVO study may be the 
early initiation of treatment, because only CRVO cases 
with a duration of symptoms of no more than 8 weeks 
were included. This finding may support early treatment 
regimens in CRVO in general. Additionally, the rate of 
ischemic retinal vein occlusion was very low in our study 
population, and patients with previous treatment were 
excluded. Another reason may be that the strict exclusion 
criteria for systemic illnesses based on the IH recom-
mendations on average resulted in a systemically healthy 
patient group. Progressive heart disease, uncontrolled 
 arterial hypertension as well as previous fortified antico-
agulation treatment were exclusion criteria.
 The disadvantage of delayed treatment has been a ma-
jor concern in CRVO. In the CRUISE study, eyes treated 
with ranibizumab 0.5 mg showed a gain of  ≥ 3 lines in 51% 
of the eyes after 12 months compared to only 33% of those 
eyes for which treatment was initiated with a delay of 6 
months  [23] . Epstein et al.  [22] also detected a less favor-
able outcome if intravitreal bevacizumab treatment was 
delayed for 6 months (60% with bevacizumab vs. 33% 
with sham/bevacizumab). In an early prospective case se-
ries with intravitreal bevacizumab treatment, we found 
no significantly reduced visual acuity prognosis within a 
3-month time period of delayed therapy initiation  [9] . In 
the RAVO study, a 2-month delay of intravitreal ranibi-
zumab treatment did not result in reduced visual acuity 
results in early CRVO cases, at least if IH was performed. 
 From the findings of this study, it may be considered 
to initiate treatment with IH in early CRVO subjects 
without major health risks, especially if there is no early 
access to intravitreal treatment with ranibizumab. It also 
seems feasible for patients anxious about intravitreal drug 
therapy to start treatment with IH and initiate intravit-
real ranibizumab treatment after 6–8 weeks if necessary. 
This would allow detection of a spontaneous response to 
IH and give these patients time to adapt to the thought of 
IVI. In the RAVO study, IH with delayed intravitreal ra-
nibizumab treatment reduced the amount of necessary 
IVI over the 12-month period and did not result in a 
worse visual acuity outcome after 12 months.
 During the first year of the CRUISE study, an average 
of 8.8 injections were given in the ranibizumab 0.5-mg 
treatment arm  [23] . In the ROCC study, an average of 4.3 
injections of ranibizumab were needed during a 6-month 
period  [20] . In order to reduce the amount of injections 
needed, laser photocoagulation of ischemic peripheral 
retinal areas has been discussed. However, a study by 
Spaide  [24] showed no significant effect on the number 
of ranibizumab injections. In the RAVO study, 5.5 and 
3.2 IVI of ranibizumab 0.5 mg were needed during the 
12-month period. Though this study was not designed to 
answer this question, further evaluation might be neces-
sary with regard to whether additional IH might have a 
beneficial effect on the increase in perfusion and the de-
crease in VEGF release, thus reducing the likelihood of 




















   
   
   
   
   
   
   
   
   
   
   


























 To note, at baseline, patients in group II on average had 
a significantly shorter duration of symptoms and a ten-
dency towards reduced CRT. Consequently, patients in 
group II might have had a shorter progression of disease 
with decreased chances of pathology. Hence, a possible 
impact on the results in group II eyes – resulting in a re-
duced number of injections and noninferior visual acuity 
at 12 months despite delayed treatment with ranibizumab 
– cannot fully be excluded. However, as there was no sta-
tistically significant difference in baseline visual acuity, we 
believe that the slight difference in the history of CRVO 
plays a minor role in the final outcomes. Nonetheless, the 
reduced sample size is still a weak point of the study.
 In summary, in the RAVO study, IH with prompt and 
deferred intravitreal treatment with ranibizumab 0.5 mg 
for early CRVO resulted in high rates of increase in vi-
sual acuity over a 12-month period. IH alone resulted in 
visual acuity recovery in about one third of the patients. 
From our data, it seems reasonable to primarily treat pa-
tients anxious about intravitreal drug therapy, without 
major systemic risk factors and with early CRVO with IH 
initially. If spontaneous recovery cannot be achieved, ini-
tiation of intravitreal treatment with ranibizumab 0.5 mg 
improves the chances of visual acuity recovery.
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